ProQR Therapeutics NV closed a public offering of ordinary shares raising about $57.5 million in gross proceeds.
The Leiden, Netherlands-based biopharmaceutical company sold 10,454,545 ordinary shares at $5.5 apiece. This includes 1,363,636 additional shares sold as underwriters fully exercised the overallotment option.
The company previously said it plans to use net proceeds from the offering to fund ongoing research and development activities, for working capital and for other general corporate purposes.
The Dutch biopharmaceutical company develops treatments for genetic disorders.
Citigroup Global Markets and Evercore ISI were joint book-runners for the offering, while Cantor Fitzgerald & Co. and JMP Securities were lead managers. Chardan and Kempen were co-managers.